A Study of Pegylated Interferon Alfa-2b (MK-4031) as an Adjuvant Treatment in Japanese Patients With Malignant Melanoma (MK-4031-370)
Clinical trial NCT01636960 · TERMINATED
Trial details
- NCT number
- NCT01636960
- Sponsor
- Merck Sharp & Dohme LLC
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2012-12-25
- Primary completion
- 2014-03-26
- Enrollment
- 9
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.